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Summary
Objective: This study evaluates the viscosupplementation material Hylan A and B in relation to its: (1) joint distribution, residence time and
mechanism of removal and/or degradation, and (2) associated synovial ﬂuid leukocyte response, in a goat model.
Method: One green ﬂuorophore was covalently bound to the Hylan A low molecular weight (MW) molecule (viscous ﬂuid fraction) and a sec-
ond red ﬂuorophore was covalently bound to Hylan B high MWmolecule (globule gel-like fraction). Goats were anesthetized and the right knee
received 0.5 ml of test material or unbound ﬂuorophore dyes. Gross and histological serial evaluations were performed over an 8-week period.
Results: By 24 h, the non-covalently linked control labels were not present in the tissues. For the covalently linked labels, the green ﬂuoro-
phore Hylan A diminished rapidly in intensity grossly but persisted to 28 days within the superﬁcial synovial and articular cartilage layers
in histologic sections. The red ﬂuorophore linked Hylan B was seen only as globules in the synovial ﬂuid. Mononuclear cells remained attached
to these globules for 28 days and showed phagocytosis of the globules as well as the green ﬂuorophore Hylan A. The globules were absent at
56 days after injection. The synovial ﬂuid leukocyte count peaked at 24 h (mean 9767 cells/mm3 8574 S.D.) and declined by 7 days.
Conclusions: The smaller MW Hylan was removed more rapidly than the higher MW Hylan. The globules were degraded by a different mech-
anism involving monocytes/macrophages on the surface of the higher MW globules.
ª 2006 OsteoArthritis Research Society International. Published by Elsevier Ltd. All rights reserved.





Osteoarthritis (OA) is a degenerative disease with associ-
ated alterations in the involved joint’s biomechanics and
biochemical status. The articular cartilage is a unique avas-
cular tissue that is unable to regenerate itself and reverse
the degenerative process. Current studies have shown
that active inﬂammatory components contribute to the OA
degenerative process. Clinical signs suggesting an inﬂam-
matory process include joint swelling, stiffness and synovial
effusion. At the cellular and molecular level, OA represents
an imbalance between chondrocyte anabolic and catabolic
processes. The synovium from OA patients has resem-
blances of synovium from early rheumatoid arthritis patients
with increased cellularity and vascularity. It stains for two
cartilage destructive cytokines associated with the inﬂam-
matory response, i.e., interleukin-1 beta (IL-1beta) and tu-
mor necrosis factor-alpha (TNF-alpha)1.
Interleukins (ILs) are a family of interrelated cytokines
that regulate the acute inﬂammation process. The proin-
ﬂammatory cytokines, such as IL-1beta, typically works in
conjunction with receptors, receptor antagonists and other
factors such as TNF-alpha. These are key inducers in initi-
ating catabolic and articular cartilage degenerative changes
that are facilitated by matrix metalloproteinases (MMPs)
and aggrecanase that degrade the extracellular matrix2e7.
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type II collagen and proteoglycans in chondrocytes8e10.
Nitric oxide (NO), which is released from chondrocytes dur-
ing inﬂammation, further contributes a proinﬂammatory
effect and in experimentally induced OA, induces chondro-
cyte apoptosis that ultimately results in reduced matrix syn-
thesis and cartilage degradation. The pathways and targets
involved with these inﬂammatory processes are, at present,
not completely understood as they are complex and have
considerable cross talk. However, these pathways do repre-
sent potential treatment sites and can potentially facilitate
monitoring of therapeutic efﬁcacy and understanding
mode(s) of action.
Present therapeutic pharmacologic approaches have fo-
cused on pain relief and include systemic analgesics (acet-
aminophen, non-steroidal anti-inﬂammatory drugs (NSAIDs),
cyclooxygenase-2 (cox-2) inhibitors, and opioids), and
localized treatment including intra-articular injections with
glucocorticoids and viscosupplementation agents (hyalur-
onan (HA) [hyaluronic acid], sodium hyaluronate, or Hylan),
and topical agents (methylsalicylate and capsaicin)11.
Viscosupplementation is a current treatment adminis-
tered to some patients with symptomatic OA of the
knee12e26. The initial objective of viscosupplementation is
to augment the viscoelastic properties of OA synovial ﬂuid,
which has been shown to have a lower concentration and
molecular weight (MW) of hyaluronic acid compared to
healthy ﬂuid27. There are currently ﬁve commercially avail-
able hyaluronate or hyaluronate derived viscosupplementa-
tion agents available in the United States and include sodium
hyaluronate (Supartz, Smith and Nephew Inc., Memphis,
TN), sodium hyaluronate (Hyalgan, Sanoﬁ-Synthelabo48
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tech Products, Bridgewater, NJ), sodium hyaluronate
(Euﬂexxa), a bacterial cell derived HA, (Ferring Pharma-
ceutical, Inc., Suffern, NY), and Hylan G-F 20 (Synvisc,
Wyeth-Ayerst, Philadelphia, PA). Hylans are made by cova-
lent cross-linking of separate HA molecules which produces
polymers in theory possessing increased viscoelasticity,
lubricity and resistance to degradation. The recommended
viscosupplementation regime, depending on which product
is used, includes a series of three or ﬁve injections spaced 1
week apart28e32. These injections are recommended to be
administered into intra-articular space of (dry) knees in
which effusions are not detectable and require accurate
needle placement33.
There is a growing body of evidence that suggests HA in-
teracts with its receptors such as CD44, intracellular adhe-
sion molecule-1 (ICAM-1) and receptor for HA mediated
motility (RHAMM)34 resulting in reduced expression of IL-1
and MMPs in cartilage and synovium35, reduced prosta-
glandin E2 (PGE2) concentration in synovial ﬂuid
36,37, and
lowered levels of MMP-3 and tissue inhibitor of metallopro-
teinases (TIMP) in chondrocytes (bovine) and synovial cells
(human and rabbit)36,38. Moreover, HA may limit the syno-
vial inﬂammatory response to OA changes in the joint39.
Clinically, viscosupplementation appears to be generally
well tolerated with an incidence of local reactions reported
to be between 0% and 13%21,25,26,40,41, which compares
with placebo26,40. In addition, there have been reports of re-
activity in some patients to the second or third injection of
some viscosupplementation agents42e46. The beneﬁts of
viscosupplementation are felt to extend beyond the resi-
dence time of HA, although there is a paucity of information
relative to the metabolism and residence time of intra-artic-
ular Hylan based viscosupplementation.
This current study was designed to address two clinical
questions that arose while utilizing viscosupplementation
in our patients: (1) What was the actual joint distribution,
residence time and mechanism of removal and/or degrada-
tion of the viscosupplementation material we were using?
(2) What accounted for the presence of mononuclear cellsclustered on the surface of globular gel-like structures within
the synovial ﬂuid (Fig. 1) that we documented in aspirates
from small volume effusions in six patients that developed
within the week following a viscosupplementation injection?
Methods
EXPERIMENTAL DESIGN
A Spanish goat model was chosen in this IACUC
approved project to study a viscosupplementation agent
containing a mixture of two types of Hylan and to document
at serial time points its knee (stiﬂe) joint distribution, joint res-
idence time and removal or degradation of the soluble Hy-
lan-A component (MW of 4e6 million) and the gel Hylan-B
component (a cross-linked form of Hylan A) of the viscosup-
plementation material we were using clinically.
This was a study conducted in three phases (Table I). In
phase 1, intra-articular injections were done of ‘‘control
material’’ that contained the two ﬂuorophore compounds
that were non-covalently linked to the two Hylans in order
to determine if the ﬂuorophores had non-speciﬁc binding to
joint tissues and if they would be suitable labels for detec-
tion. In phase 2, intra-articular injections were done of
‘‘test material’’ that contained the two ﬂuorophore com-
pounds that were covalently linked to the two Hylans to
establish the time frame of the study and dosage size ef-
fects. For the dosage size effects, bilateral 0.5 ml and
1.5 ml injection volumes were used. In phase 3, the num-
ber of animals was increased per group to receive the
0.5 ml intra-articular injections of test material, the study in-
terval was extended, and only one knee was injected to
determine if diffusion cross-over to the contralateral joint
occurred. A total of 36 skeletally mature female Spanish
goats were used in this study. The goats were euthanized
at time 0, 3, 6, 24 h, 7, 28 and 56 days after injections47.
The joints were opened, synovial ﬂuid collected, and then
tissue specimens were collected and processed for histo-
logic analysis.Fig. 1. (A) Microscopic appearance of the gel-like globules observed in human synovial ﬂuid 1 week after the ﬁrst injection. Original magniﬁ-
cation 60. (B) Higher power view of the globule is shown in (A) and demonstrating cells attached to the surface. Original magniﬁcation 300.
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Study schedule and injection volumes used
Time* Number of goats Study phase Treatment Injected volume (cc)
Left knee Right knee
T-0 2 1 Non-linked ﬂuorophoresy þHylan A and B 1.5 0.5
2 2 Fluorophores linked to Hylan A and Bz 1.5 0.5
3 h 2 1 Non-linked ﬂuorophoresy þHylan A and B 1.5 0.5
2 2 Fluorophores linked to Hylan A and Bz 1.5 0.5
6 h 2 1 Non-linked ﬂuorophoresy þHylan A and B 1.5 0.5
2 2 Fluorophores linked to Hylan A and Bz 1.5 0.5
4 3 Fluorophores linked to Hylan A and Bz 0 0.5
24 h 2 1 Non-linked ﬂuorophoresy þHylan A and B 1.5 0.5
2 2 Fluorophores linked to Hylan A and Bz 1.5 0.5
4 3 Fluorophores linked to Hylan A and Bz 0 0.5
7 days 2 2 Fluorophores linked to Hylan A and Bz 1.5 0.5
4 3 Fluorophores linked to Hylan A and Bz 0 0.5
28 days 2 2 Fluorophores linked to Hylan A and Bz 1.5 0.5
56 days 4 3 Fluorophores linked to Hylan A and Bz 0 0.5
Total 36
*Evaluation interval after injection.
yThe green ﬂuorophore (Alexa Fluor 488) and red ﬂuorophore (Alexa Fluor 594) were not covalently linked to the Hylan A and B molecules,
respectively. Hylan A and B were present in the mixture.
zThe green ﬂuorophore (Alexa Fluor 488) and red ﬂuorophore (Alexa Fluor 594) were covalently linked to the Hylan A and B molecules,
respectively.TEST AND CONTROL MATERIALS
The test and control materials were a custom dual ﬂuoro-
phore labeled preparation containing 80% Hylan A and 20%
Hylan B and was supplied sterile for injection by Genzyme
Biosurgery (Division of Genzyme Corp., Boston, MA)
(Fig. 2)48,49. The ﬂuorophores used were Alexa Fluor 488
(green), used with the Hylan-A molecule, and Alexa Fluor
594 (red), used with the Hylan-B molecule (Molecular
Probes, Inc., Eugene, OR).
INJECTION OF TEST MATERIAL
All injections were performed under strict asepsis. All an-
imals had food and water removed 24 h before treatment
and were premedicated with xylazine hydrochloride, 1 mg/kg
IM. After 3e5 min, ketamine hydrochloride, 4.5 mg/kg IM,
was administered. Animals received pretreatment penicillin
(Bicillin LA with Procaine e 1.2 million units, deep IM) for
prophylaxis. The knee was prepared for injection with a po-
vidone-iodine scrub, alcohol rinse, and betadine applica-
tion. A 3.5-inch by 19-gauge needle was introduced into
the intra-articular space via an anteromedial or anterolateral
approach and test material or control material was injected
(Table I). After removal of the needle, the knee was then cy-
cled 20 times through a full range of motion. For phases 1
and 2, the injection procedure was repeated in the opposite
knee (Table I).
HISTOLOGICAL EVALUATION
After euthanasia and synovial ﬂuid collection, the follow-
ing tissues were collected from the joint: synovium (poste-
rior pouch, suprapatellar pouch, medial and lateral
aspect), fat pad, anterior cruciate ligament (ACL), posterior
cruciate ligament (PCL), ligamentum mucosum, articularcartilage from the anterior medial condyle, posterior medial
condyle, anterior lateral condyle, posterior lateral condyle,
condyle groove junction, trochlea (proximal and distal), pa-
tella, lateral tibial plateau, medial tibial plateau, medial me-
niscus, lateral meniscus and popliteal lymph node. These
tissues were placed in 10% phosphate buffered formalin
and shipped to Genzyme for histological processing. Two
sections were obtained from each tissue, one section was
stained with hematoxylin eosin stain and one section was
left unstained. The tissue sections were returned to the au-
thors for ﬂuorescent microscopic analysis for the ﬂuoro-
phores. One of the authors (TMS) read all the slides in
a blinded manner. The presence of the ﬂuorophore in the
various unstained tissue sections and penetration was re-
corded as semi-quantitative data using a grade score as fol-
lows: 0¼ no visible ﬂuorophore ﬂuorescence, þ1¼ very
weakly positive ﬂuorescence (barely detectable), þ2¼
weakly positive ﬂuorescence (detectable but at lower inten-
sity than grade þ3), and þ3¼ positive bright intensity
ﬂuorescence. The natural autoﬂuorescence of the joint tis-
sues, considered to be grade 0, was evaluated in a separate
set of comparable native tissues (historical specimen from
an age, sex and species matched goat) that did not receive
any injections or treatments (negative control) and were
similarly processed by Genzyme for histologic sections.
Results
The green ﬂuorophore (Alexa Fluor 488) was a good in-
dicator of tissue distribution that could even be detected
grossly using a hand held shortwave UV source. The red
ﬂuorophore (Alexa Fluor 594) with longwave UV did not
demonstrate ﬂuorescence as brightly as the green ﬂuoro-
phore. It had a distinct small globular pinkeorange appear-
ance in the covalently linked form (Fig. 2).
1251Osteoarthritis and Cartilage Vol. 14, No. 12Fig. 2. Appearance of the shortwave or longwave ultraviolet illumination of the dual ﬂuorophore labeled Hylan preparation used for injection in
this study. (A) The drop of the test material on a glass slide shows the green ﬂuorescence of the green ﬂuorophore linked Hylan-A component
and within the drop are small dark spots (arrows) that are the Hylan-B globules. (B) Same as (A) except under longwave UV illumination and
showing the reddish hue of the red ﬂuorophore linked Hylan-B globules (arrows). (C) A close-up image of a tuberculin syringe ﬁlled with the
test material shows the homogeneous green ﬂuorescence of the Hylan-A component and the small reddish ﬂuorescent globular Hylan-B com-
ponents of the test material (arrows).SYNOVIAL FLUID MICROSCOPIC ANALYSIS FOR
FLUOROPHORES (TABLE II)
The synovial ﬂuid specimens were observed to have test
material green ﬂuorophore and similarly the red ﬂuorophore
in all but one goat at the 28-day evaluation interval. No ﬂu-
orophores were detected in the 56-day post injection spec-
imens. The gel-like globules were seen grossly on the
surfaces of the articular cartilage at the shorter post injec-
tion intervals (Fig. 3). The red ﬂuorophore was easily
detected as bright red gel-like globules present in the syno-
vial ﬂuid and these diminished in size and number with time.
These globules were generally not visible under bright ﬁeld
illumination but they could be seen with contrast enhance-
ment illumination. They also became visible when cells out-
lined and/or attached to their surface (Fig. 4). The cells
attached to the surfaces of the globules were predominantly
monocytes/macrophages as shown in Giemsa stained
preparations and demonstrated phagocytosis of the green
ﬂuorophore (Fig. 4). At the 28-day interval, cell aggregates
with small gel-like globules were observed in the synovial
ﬂuids. The green ﬂuorophore could be detected (þ3) inFig. 3. Twenty-four-hours post injection, 1.5 cc injection of test mate-
rial, pre-lavage.Grossappearanceof the femoral condyles and show-
ing gel-like globules (arrows) on the surface of the articular cartilage.
1252 D. W. Jackson and T. M. Simon: Viscosupplementation joint residence timeFig. 4. Seven-days post injection, 1.5 cc injection of test material. (A) Appearance of synovial ﬂuid under bright ﬁeld illumination and showing
a gel-like globules covered with white blood cells (WBCs) and WBCs that are present in the synovial ﬂuid in high numbers. Original magni-
ﬁcation 60. (B) Same ﬁeld as in (A), but under red excitation ﬂuorescent illumination and showing the gel-like globules brightly shows the red
ﬂuorophore. (C) Shows WBCs that are on the surface of a gel-like globule. Original magniﬁcation 150. (D) Same ﬁeld as in (C), but under
green excitation ﬂuorescent illumination and showing the green ﬂuorophore uptake by the cells.the synovial ﬂuid and within leukocytes in the synovial ﬂuid
and within the cells (monocytes/macrophages) attached to
the surface of red ﬂuorophore þ3 positive gel-like globules.
Over the study interval the intensity of the green ﬂuorophore
in the ﬂuid portion of the synovial ﬂuid diminished but was
very bright within the cells that were usually adhered to
the surface of the gel-like globules.
The synovial ﬂuid leukocyte count was observed to in-
crease shortly after the test material injection and spiked
at 24 h after injection, then declined by the 7-day evaluation
point (Table II). The results of synovial ﬂuid differentials are
presented in Table II and shows the initial monocyte popu-
lation is generally shifted to predominately polymorphonu-
clear leukocytes (PMNs) by 3e24 h after injection.
HISTOLOGIC ANALYSIS
The stained sections were useful for identiﬁcation of
speciﬁc structures or cells not readily apparent in the
unstained sections. In general, the brightness of both ﬂuoro-
phores in the histologic tissue sections ranged from þ3 pos-
itive to none visible (grade 0) or at the level of natural
autoﬂuorescence of the tissue (also grade 0). The green
ﬂuorophore was visually more detectable (brighter) in the
tissues than the red under ﬂuorescent microscopy although
some red gel-like globules (0.5 mm in size) were seen adja-
cent to the tissues. In the latter case, the globules wereidentiﬁed as positive staining although the tissue generally
showed no internalization or deep tissue distribution of the
red ﬂuorophore globule. The natural autoﬂuorescence of
the tissues was evaluated in a separate set of comparable
Table II
Synovial fluid analysis for fluorophores, white blood cell count, and













T0 46 37 0 0 55 37 14 1
3 h 77 24 0 0 23 24 1363 265
6 h 65 34 0 0 35 34 500 359
24 h 73 25 4 7 24 26 9767 8574
7 days 78 13 0 1 22 13 761 559
28 days 21 7 1 1 78 9 379 129




43 34 0 0 57 34 213 161
*PMN¼ polymorphonuclear leukocytes; Lympho¼ lymphocytes;
Mono¼monocytes.
1253Osteoarthritis and Cartilage Vol. 14, No. 12Fig. 5. (A) This photo of articular cartilage from the anterior medial femoral condyle shows the less commonly observed uptake of the green
ﬂuorophore by chondrocytes/lacunae under ﬂuorescent microscopy. Typically, only the superﬁcial layer of articular cartilage shows uptake. (B)
Same tissue specimen as in (A) except section was H&E stained.native tissues that did not receive any injection (negative
control). These negative control tissues demonstrated an
extremely low level of green ﬂuorescence that was consid-
ered negative (grade 0) and no red ﬂuorescence and pro-
vided a means to compare the low levels of ﬂuorescence
seen in the test material groups.
In some articular cartilage sections the green ﬂuorophore
was detected in the tangential zone of the cartilage as well
as in the lacunae (Fig. 5). In the synovium, ﬂuorophores
usually appeared in the surfaces or edges rather than
deep penetration within the tissue substance [Fig. 6(A,
B)]. Blood vessels were an exception as green ﬂuorescence
was occasionally detected in the lumen in superﬁcial and
deep tissue at 24 h after injection. The popliteal lymph no-
des from the legs of the injected knees were observed to
have detectable green ﬂuorophore either in blood vessels,
or cells (usually monocytes/macrophages), or in trabeculae
channels.
Small (0.5 cc) vs large (1.5 cc) injection volume effects
At time zero, both volumes provided very weak (þ1) to
positive (þ3) ﬂuorescence in the various tissues and there
was a tendency to have more tissues that are þ3 positive
in the knee injected with the larger volume. At the later
time intervals, the knees that received the 1.5 cc injection
volume generally showed more tissues with detectable þ1
ﬂuorescence than the knees with the smaller 0.5 cc injec-
tion volume.
The ﬂuorophores were detectable in most joint tissues up
to 28 days. This longer residence time of the covalently
bound ﬂuorophore labeled test material is in contrast to
the unbound ﬂuorophores that were cleared from the
joint tissues relatively rapidly and none were observed by
24 h after injection. No ﬂuorophores (grade 0) were de-
tected in the joint tissues at the 56-day post injection
interval.Discussion
This study in the goat model was stimulated by and dem-
onstrated similar responses to observations in six patients
that developed small effusions following one injection of
Hylan A and B. This animal model not only demonstrated
similar globular components within the synovial ﬂuid but in
addition demonstrated similar mononuclear cells attached
to their surface. The patients demonstrated transient eleva-
tions of the synovial ﬂuid leukocyte count (range 250e3800
leukocytes per mm3) as well as the presence of globular
(range 0.25e1.0 mm maximum dimension) components.
This cellular response in these six patient’s synovial ﬂuid
was not the pseudosepsis reactions that had been previ-
ously described; also known as severe acute inﬂammatory
reaction (SAIR). SAIR has been characterized by the acute
onset of a painful swollen warm knee resembling a septic
knee. Aspiration of SAIR associated tense effusion often re-
vealed a much higher leukocytes count (5000e80,000 leu-
kocytes per mm3)42e44. The SAIR patients had negative
cultures and the reaction was usually seen after the second
or third injection in their series of three injections43. The
transitory synovial ﬂuid leukocyte response should be
discerned from septic secondary arthritis with its potentially
serious complications and also from crystal induced
inﬂammations50.
This presence of a transitory increase in synovial ﬂuid
PMNs and monocytes that we are describing following the
initial intra-articular space injection was a regular occur-
rence in the animal model. This transient synovial ﬂuid
leukocyte response was associated with monocytes/macro-
phages attaching on the surface of the globules. These sur-
face clusters of cells appear to be activated and
progressively phagocytized the large Hylan-B globules.
The distribution of these red ﬂuorophore linked Hylan-B
globules demonstrated they were randomly adherent in
localized areas to the articular surfaces (Fig. 3) or ﬂoating
1254 D. W. Jackson and T. M. Simon: Viscosupplementation joint residence timeFig. 6. (A) This photograph shows the green ﬂuorophore uptake by the superﬁcial synovial layers and blood vessels over the ACL. (B) Low
power view of the unstained tissue section shown in (A). The collagen ﬁber bundles in the ACL are evident and the rectangle shows the area of
interest enlarged in (A).in the synovial ﬂuid (Fig. 4). The synovial ﬂuid mononuclear
cells aggregated to and remained attached to the surfaces
of these globules. These surface cells showed ongoing
phagocytosis of the globules as well as uptake of some of
the intra-articular green ﬂuorophore Hylan-A component.
The presence of the mononuclear cells on the surface of
the globules raises the concerns for the potential of granu-
loma formation50. We did not see evidence of granuloma
formation in the synovium in any of the animals studied
and the globular components were removed from the in-
tra-articular space by 56 days.
The distribution of the test material ﬂuorophores was con-
sistent. The commonly observed staining pattern for thegreen ﬂuorophore (soluble Hylan-A component) in the joint
tissues was at the superﬁcial layers and edges and surface
cells (especially synovium), blood vessels lumen contents
(early interval), and fat pad cells (later interval) and, less fre-
quently, positive staining of chondrocytes in lacunae in the
very superﬁcial layers. The popliteal lymph nodes were of-
ten observed to have detectable green ﬂuorophore either
in blood vessels, or cells (usually monocytes/macrophages),
or in trabeculae channels. A relatively short residence time
of hyaluronic acid has been anecdotally suggested in the lit-
erature51e53. From gross inspection in this study, the green
ﬂuorophore linked Hylan A diminished rapidly in intensity
over 2 days but persisted in trace amounts microscopically
1255Osteoarthritis and Cartilage Vol. 14, No. 12for up to 28 days in superﬁcial synovium and articular carti-
lage. The Hylan residence interval we are describing does
not explain the reported longer analgesic effects and sug-
gests other possible biological mechanisms may be
involved.
The cell populations associated with the surface of the
globules and the transient rise in synovial ﬂuid leukocyte
count are an area of interest deserving further study. In
this study, the monocytes/macrophage populations are
likely activated since they were adherent to and phagocytiz-
ing the globules. They may be exhibiting unique up or down
gene regulation or expression, demonstrating unique sur-
face regulatory receptors and/or producing cytokines.
These expressions may all impact the inﬂammatory pro-
cesses and pathways within the knee joint and this could
be consistent with the literature suggesting a role of visco-
supplementation on the inﬂammatory process. In terms of
the OA knee environment, these adhered synovial leuko-
cytes are likely participating in the complex interactions of
cytokines and the inﬂammatory process as well as the sy-
novial lining cells and chondrocytes. IL-1beta (involved in
early and late stage OA) and TNF-alpha (primarily involved
at onset of OA) are the principal proinﬂammatory and cata-
bolic cytokines concerned with the initiation and progres-
sion of articular cartilage destruction and can be produced
by chondrocytes54. IL-6 and IL-8 are other regulatory cyto-
kines. IL-1beta and TNF-alpha can induce or stimulate
PGE2 and NO production, which leads to cell injury and in-
creased susceptibility of chondrocytes to cytokine induced
apoptosis55. Chondrocyte apoptosis is an important contrib-
utor to articular cartilage degeneration since chondrocytes
are the only means of making and maintaining the cartilage
extracellular matrix. OA chondrocytes produce excessive
PGE2 and NO
55. The NO level mediates many functions
and can stimulate free radicals associated with cartilage
matrix degradation, inhibition of aggrecan and collagen syn-
thesis, increases MMPs, increases chondrocyte apoptosis,
and reduces IL-1ra (antagonist to IL-1beta)56. PGE2 can ex-
ert catabolic and anabolic effects depending on the local
environment.
Intra-articular injection of Hylan represents a localized
treatment that could affect the cytokine induced inﬂamma-
tory environment. NO levels have been reported to be re-
duced after HA and Hylan treatment57. Smith showed that
prostaglandin concentration was lower after HA injection
in a canine model of OA58. It would also be of interest to de-
termine if Hylan is stimulatory for the inhibitory cytokines
such as IL-4, -10, -13, and IL-1ra. For these HA interactions,
the CD44 receptor plays an important role. HA has been re-
ported to penetrate articular cartilage and bind to the CD44
receptor and results in inhibition of IL-2b stimulated produc-
tion of MMP-1, -3, and -13 (in vitro)59. The HA bound CD44
receptor also mediates motility (RHAMM) that modulates
cell proliferation migration and gene expression in MW
dependent manner with more effect with higher MWs60.
We observed Hylan A penetration into articular cartilage
and to chondrocytes/lacunae in this goat model.
It is also possible that degenerative articular cartilage de-
bris and complexes present in the joint in certain patients
might beneﬁt from being phagocytized as well resulting
from a ‘‘cell mediated lavage’’. Such reactions and pro-
cesses may (or may not) be beneﬁcial for the patient and
merit further study.
The detection of the ﬂuorophores was done visually and
was subjective. To reduce the potential for variability, one
person made all of the ﬂuorophore assessments for the his-
tologic sections (read blinded). This subjective assessmenthas limitations in statistical quantitative interpretation of the
data.
This animal model demonstrates that following viscosup-
plementation using Hylan test material there is a transient
elevation of synovial ﬂuid leukocytes peaking at 24 h and
subsiding within 1 week without further sequelae. This is
similar to transitory responses observed in humans after
Hylan administration. The globular (larger cross-linked
MW component) is phagocytized by surface cells arising
in the synovial ﬂuid. The joint residence time for the more
soluble component is signiﬁcantly shorter and removed
primarily by a non-cellular process in a much more rapid
manner than the gel form. Hylans appear to affect a variety
of biological mechanism including anti-inﬂammatory effects,
transient restoration of viscoelasticity, and normalization of
HA synthesis that are worthy of further study.
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